Bajaj Healthcare has surged by 7.1% this week, reaching Rs.305.25 – outpacing the Sensex's minimal 0.5% growth. Interestingly, despite a strong 'Sell' recommendation, the stock appears to be recovering from its 52-week low, indicating mixed market sentiments.

Bajaj Healthcare reported a Q4 net loss of ₹22.9 crore, with a slight decrease in revenue year-over-year (YoY). However, there was a significant increase in EBITDA by 93% YoY to ₹22.7 crore. The board proposed a dividend of ₹1.50 per share for the fiscal year 2026.

Bajaj Healthcare reported a significant 12.6% year-on-year increase in revenue for FY26, primarily due to a strong 51.6% growth in Active Pharmaceutical Ingredient (API) exports. Moreover, the company's profit after tax (PAT) increased by 19.3% in Q4 FY26, with 41 new Drug Master Files (DMF) approved, bringing their global total to 110.

Bajaj Healthcare's Q4 net loss has expanded significantly, reaching ₹194 million compared to ₹112 million in the same period last year. The company's revenue also saw a minor dip, decreasing from ₹1.54 billion to ₹1.53 billion year-on-year.

Bajaj Healthcare receives approval from NSE and BSE to list 20.79 lakh additional shares, following the conversion of warrants, with a face value of Rs. 5 per share.